New immune cell therapy tested in kids with aggressive leukemia

This early-stage study is testing the safety and feasibility of a new type of treatment called CAR-T cell therapy for children and young adults (ages 1-29) with B-cell acute lymphoblastic leukemia (ALL) that has come back or not responded to standard chemotherapy. Doctors take a patient's own immune cells (T cells), modify them in a lab to better target cancer cells, and then infuse them back into the patient. The main goal is to see if this process is safe and manageable, while also checking for early signs that it might help control the cancer.